The comparison between CHOP and R-CHOP in primary gastric diffuse large B cell lymphoma
Annals of Hematology, 07/05/2012
Sohn BS et al. – The addition of rituximab was not found to have an impact on patients’ outcomes with primary gastric diffuse large B cell lymphoma (DLBCL). The β2–microglobulin in primary gastric DLBCL might be able to discriminate the patients’ prognosis who are treated with rituximab–cyclophosphamide, doxorubicin, vincristine, and prednisolone (R–CHOP) chemotherapy.